Angiotensin converting enzyme inhibition: from viper to patient

Angiotensin converting enzyme inhibition: from viper to patient.

The story of angiotensin converting enzyme (ACE) inhibitors started approximately 50 years ago, when it was discovered that human plasma incubated with the venom of the Brazilian viper, Bothrops Jararaca, generated a hypotensive compound. This discovery quickly led to the characterisation of the active principle of the venom by Fereira and Greene as a family of peptides, which were named bradyk...

Angiotensin Converting Enzyme in Sarcoidosis

Nephrectomy, converting enzyme inhibition, and angiotensin peptides.

To determine the contribution of kidney-derived renin and angiotensin converting enzyme to circulating and tissue levels of angiotensin peptides, we measured angiotensin (Ang)-(1-7), Ang II, Ang-(1-9), and Ang I in plasma, kidney, lung, heart, aorta, brown adipose tissue, adrenal, pituitary, and brain of five groups of male Sprague-Dawley rats: control rats, rats given the converting enzyme inh...

Angiotensin-converting enzyme inhibition and diabetic nephropathy.

Hypertension and diabetes mellitus are strongly associated conditions from epidemiologic, genetic, and pathophysiologic points of view. The prevalence of hypertension is high in patients with diabetes, and, conversely, many patients with essential hypertension are glucose intolerant. Proteinuria appears in 40-50% of patients with insulin-dependent diabetes mellitus and 20-30% of patients with n...

Role of Tissue Angiotensin-Converting Enzyme Inhibition

Background Chronic treatment with high doses of angiotensin-converting enzyme (ACE) inhibitors prolongs survival after myocardial infarction. Since the plasma reninangiotensin system (RAS) is not consistently activated in the chronic phase after myocardial infarction, the beneficial effects of ACE inhibition have been attributed, in part, to inhibition of an activated tissue RAS. However, a rel...